By Lew Kizer — 2026-11-21 — Health & Nutrition
The short answer
On Nov. 19, 2026, at the International Celiac Disease Symposium in Melbourne, Interlude Biopharma said the FDA has cleared a Phase 3 trial of larazotide acetate, an oral pill meant to tighten the gut lining. About 414 people ages 12 to 80 with well-controlled celiac disease will take the drug or a placebo while eating a study bar with 500 mg of gluten for 12 weeks. The trial is expected to start in the U.S. in early 2027. Larazotide is not approved, no celiac drug is, and the gluten-free diet remains the only treatment.
Key facts
- Interlude Biopharma, based in Miami, announced the trial Nov. 19, 2026, at the 21st International Celiac Disease Symposium (ICDS 2026), held Nov. 17-20 in Melbourne, Australia.
- Larazotide acetate is an oral, locally acting peptide that the company describes as a zonulin inhibitor that regulates tight junctions in the gut lining.
- Design per the company: randomized, double-blind and placebo-controlled at up to 100 U.S. sites, with about 414 adolescents and adults ages 12 to 80 who have biopsy-confirmed, well-controlled celiac disease.
- Participants take larazotide 0.25 mg or 0.5 mg, or placebo, three times a day for 14 weeks. After a run-in, they eat a study bar with 500 mg of gluten every other day for four weeks, then daily for eight weeks.
- Main goal: the share of people who keep normal gut lining structure and symptom control.
- The company says the FDA has granted Fast Track designation and the trial's IND is in effect. Start is expected in the first quarter of 2027. Registry: NCT07944625.
- An earlier Phase 3 of larazotide, run by 9 Meters Biopharma, was stopped in 2022 after an interim analysis.
KINGSPORT, Tenn., Nov. 21, 2026 — A celiac drug that stalled four years ago is headed back to a late-stage trial with a new goal. At the International Celiac Disease Symposium in Melbourne on Nov. 19, Interlude Biopharma said the FDA has cleared a Phase 3 study of larazotide acetate to test whether it can protect people with celiac disease from accidental gluten. The company expects it to start in the U.S. in early 2027.
This article reports medical and health-policy news and is not medical advice. SmashMeals is a food company, not a medical provider, and is not affiliated with the companies or researchers named here. Talk with your doctor before you start, stop or change any medicine.
How the trial will work
About 414 people ages 12 to 80 with biopsy-confirmed, well-controlled celiac disease will be enrolled at up to 100 U.S. sites. They will take larazotide (0.25 mg or 0.5 mg) or a placebo three times a day for 14 weeks. After a run-in period, everyone eats a study bar with 500 mg of gluten, every other day for four weeks and then daily for eight weeks. The company calls that amount the upper range of what people are estimated to get by accident in real life.
The main measure is the share of people whose gut lining stays healthy and whose symptoms stay controlled, tracked with a celiac symptom diary. The registry number is NCT07944625.
Larazotide is a pill that acts in the gut. The company describes it as blocking zonulin, a protein that loosens the seals between cells in the intestinal lining, so it works before the immune reaction to gluten gets going.
Why this is a second try
Larazotide is not new. A 342-patient Phase 2b trial, published in Gastroenterology, found the 0.5 mg dose reduced symptoms in people on a gluten-free diet, according to the release. But a Phase 3 run by 9 Meters Biopharma was stopped in 2022 after an interim analysis found the study would need too many patients to show a meaningful difference from placebo. Interlude, which later took over the program, says the FDA advised a shift to this prevention-style design.
"This is the first time that a preventive trial will be performed in celiac disease," said Dr. Alessio Fasano of Harvard Medical School and Mass General Brigham for Children. "Positive results would be very promising for the entire celiac disease community."
These are the company's own descriptions and have not been tested in this trial yet. Larazotide joins other candidates in our 2026 celiac treatment pipeline guide, including ANB033, which was also slated for this week's meeting.
What it means for gluten-free families
Even if it works, larazotide would be a backup for accidents, not a way to eat gluten on purpose. The people in this study keep eating gluten-free. Until a drug is approved, the protection is in the kitchen: what goes into the food and what it touches along the way. Our celiac meal delivery page explains how our dedicated kitchen works, and gluten-free meal delivery covers ordering for pickup or shipping.
“When you order from us, you don't have to ask. You don't have to wonder. You don't have to guess. The answer is always yes — everything is gluten-free.” — Lew Kizer, Founder, SmashMeals
Hosting a celiac guest this week? Our gluten-free Thanksgiving menu is cooked in the same dedicated kitchen. Thanksgiving deadlines: Thanksgiving ordering is closed.. Checkout confirms timing. See this week's meals.
Commentary, not medical advice
The SmashMeals perspective
Every new celiac trial gives our customers hope, and we share it. But even the best result here would be a backup for an accident, not permission to eat gluten. Until something is approved, the gluten-free diet is still the treatment. That is why our whole kitchen is gluten-free.
Frequently asked questions
Would larazotide let people with celiac disease eat gluten?
No. The trial tests whether it protects against the kind of small, accidental gluten exposure that can happen even on a careful gluten-free diet. People in the study stay on a gluten-free diet.
Is 500 mg of gluten a lot?
The company calls it the upper range of estimated real-world accidental exposure.
Is this the first time larazotide has been in a Phase 3?
No. 9 Meters Biopharma stopped an earlier Phase 3 in 2022 after an interim analysis found the study would need too many patients to show a clear difference from placebo. The new trial has a different design, focused on protection during gluten exposure rather than symptom relief alone.
Can I join the trial?
It is expected to start in the U.S. in early 2027. Check ClinicalTrials.gov record NCT07944625 and talk with your gastroenterologist about whether it fits you.
Is there an approved celiac drug?
Not yet. The release notes no celiac treatment is FDA-approved. A strict gluten-free diet is still the treatment.
Sources and credits
Follow the original sources for context and verification. A reference is not an endorsement of SmashMeals.
- Interlude Biopharma Launches at the International Celiac Disease Symposium and Announces Prevention-Focused Phase 3 Clinical Trial (opens in a new tab)
Interlude Biopharma (PR Newswire via BioSpace)
Why it matters: The company release with the trial design, gluten dose, endpoint, timing and quotes.
- ClinicalTrials.gov record NCT07944625 (opens in a new tab)
U.S. National Library of Medicine
Why it matters: The trial's public registry record named in the release.
- Phase 3 study of larazotide acetate to treat celiac disease discontinued (opens in a new tab)
Beyond Celiac
Why it matters: Background on the earlier Phase 3 that was stopped in 2022.